Challenges and limitations in the interpretation of systematic reviews: Making sense of clopidogrel and CYP2C19 pharmacogenetics

Clinical Pharmacology and Therapeutics

Volumn 94, Issue 3, 2013, Pages 376-382

  Sorich, M J ^a   Polasek, T M ^b   Wiese, M D ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYP2C19 PROTEIN, HUMAN; TICLOPIDINE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ALLELE; BLEEDING; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CORONARY STENT; DATA ANALYSIS; DEATH; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; ETHNIC GROUP; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INDIVIDUAL PARTICIPANT DATA META ANALYSIS (TOPIC); LOSS OF FUNCTION MUTATION; META ANALYSIS (TOPIC); OUTCOMES RESEARCH; PERCUTANEOUS CORONARY INTERVENTION; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRIORITY JOURNAL; REGRESSION ANALYSIS; REVIEW; RISK ASSESSMENT; STATISTICAL MODEL; STENT THROMBOSIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BIOASSAY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); GENETICS; LITERATURE; METHODOLOGY; PATIENT SELECTION; PUBLISHING; STANDARDS;

ARYL HYDROCARBON HYDROXYLASES; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 CYP2C19; ENDPOINT DETERMINATION; GENOTYPE; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PUBLICATION BIAS; RESEARCH DESIGN; REVIEW LITERATURE AS TOPIC; TICLOPIDINE;

EID: 84883184552     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.100     Document Type: Review

References (67)

1. Helton, T.J., Bavry, A.A., Kumbhani, D.J., Duggal, S., Roukoz, H. & Bhatt, D.L. Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials. Am. J. Cardiovasc. Drugs 7, 289-297 (2007).
2. Mega, J.L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
3. Polasek, T.M., Doogue, M.P. & Miners, J.O. Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1. Ther. Adv. Drug Saf. 2, 253-261 (2011).
4. Sorich, M.J. & McKinnon, R.A. Personalized medicine: potential, barriers and contemporary issues. Curr. Drug Metab. 13, 1000-1006 (2012).
5. Sorich, M.J., Polasek, T.M. & Wiese, M.D. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb. Haemost. 108, 199-200 (2012).
6. Zabalza, M. et al. Meta-analyses of the association between cytochrome CYP2C19 loss-and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart 98, 100-108 (2012).
7. Bhatt, D.L. et al. Charisma Genomics Substudy: evaluation of the CYP2C19 polymorphism in a prospective, randomized, placebo-controlled trial of chronic clopidogrel use for primary and secondary prevention. http://www. clinicaltrialresults.org/Slides/CHARISMA%20Genomics.ppt . Accessed 24 January 2012.
8. Bouman, H.J. et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17, 110-116 (2011).
9. Campo, G. et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57, 2474-2483 (2011).
10. Collet, J.P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
11. Giusti, B. et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103, 806-811 (2009).
12. Harmsze, A.M. et al. The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet. Genomics 22, 169-175 (2012).
13. Harmsze, A.M. et al. Combined influence of proton-pump inhibitors, calciumchannel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J. Thromb. Haemost. 9, 1892-1901 (2011).
14. Harmsze, A.M. et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur. Heart J. 31, 3046-3053 (2010).
15. Jeong, Y.H., Tantry, U.T. & Jung, T.J. Impact of the cytochrome P450 2C19*3 polymorphism on platelet reactivity and adverse clinical events in patients with acute myocardial infarction. Eur. Heart J. 32, 313-631 (2011).
16. Ko, Y.S. et al. Association of cytochrome P450 2C19 polymorphism with clinical efficacy of clopidogrel in patients who received elective percutaneous coronary intervention [abstr.]. Korean. Circ. J. 40, 9 (2010).
17. Komarov, A., Shakhmatova, O., Donnikov, A., Ilyushchenko, T., Dzhalilova, G. & Panchenko, E. Carrying of P450 2C192 polymorphism and use of proton pump inhibitors increase risk of adverse outcomes after elective PCI in Russian patients with CAD. Eur. J. Cardiovasc. Prev. Rehabil. 18, S100-S25 (2011).
18. Malek, L.A. et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ. J. 72, 1165-1169 (2008).
19. Malek, L.A. et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology 117, 81-87 (2010).
20. Mega, J.L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119, 2553-2560 (2009).
21. Mega, J.L., Morrow, D.A., de Lemos, J.A., Mohanavelu, S., Cannon, C.P. & Sabatine, M.S. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 51, 2422-2429 (2008).
22. Mega, J.L., Topol, E.J. & Sabatine, M.S. CYP2C19 genotype and cardiovascular events. JAMA 307, 1482-3; author reply 1484 (2012).
23. Nisho, R. et al. Impact of cytochrome P450 2C19*2 polymorphism on the target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel [abstr.]. J. Am. Coll. Cardiol. 57, 1299 (2011).
24. Oh, I.Y. et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart 98, 139-144 (2012).
25. Ono, T. et al. Determination of cut-off levels for on-clopidogrel platelet aggregation based on functional CYP2C19 gene variants in patients undergoing elective percutaneous coronary intervention. Thromb. Res. 128, e130-e136 (2011).
26. Paré, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
27. Sawada, T. et al. Impact of cytochrome P450 2C19*2 polymorphism on intrastent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ. J. 75, 99-105 (2011).
28. Shuldiner, A.R. et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302, 849-857 (2009).
29. Sibbing, D. et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121, 512-518 (2010).
30. Sibbing, D. et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur. Heart J. 30, 916-922 (2009).
31. Simon, T. et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
32. Tang, X.F. et al. [Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention]. Zhonghua Xin Xue Guan Bing Za Zhi 39, 617-620 (2011).
33. Tello-Montoliu, A., Jover, E. & Marin, F. Influence of CYP2C19 polymorphisms in on-treatment platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome. Eur. Heart J. 32, 1-312 (2011).
34. Tiroch, K.A. et al. Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am. Heart J. 160, 506-512 (2010).
35. Trenk, D. et al. Cytochrome P450 2C19 681G>A polymorphism and high onclopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J. Am. Coll. Cardiol. 51, 1925-1934 (2008).
36. Wallentin, L. Genetic substudy of the PLATO trial? Authors' reply. Lancet 377, 637-638 (2011).
37. Wallentin, L. et al.; PLATO investigators. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376, 1320-1328 (2010).
38. Worrall, A., Armesilla, A. & Norell, M. The presence of the CYP p450 C192 allele is associated with impaired response to clopidogrel as measured by the VerifyNow P2Y12 near-patient testing device in patients undergoing coronary angiography [abstr]. Eur. Heart J. 30, 303-585 (2009).
39. Yamamoto, K. et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J. Cardiol. 57, 194-201 (2011).
40. Yuan, J., Tang, X.F., Yang, Y.J. & Gao, R.L. Association between cytochrome P450 2C19 681G>A polymorphisms and risk of cardiovascular events in coronary heart disease with clopidogrel in Chinese. Eur. Heart J. 32, 1-312 (2011).
41. Anderson, J.L. et al. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel [abstr.]. J. Am. Coll. Cardiol. 53, A1-A99 (2009).
42. Bauer, T., Bouman, H.J., van Werkum, J.W., Ford, N.F., ten Berg, J.M. & Taubert, D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343, d4588 (2011).
43. Holmes, M.V., Perel, P., Shah, T., Hingorani, A.D. & Casas, J.P. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306, 2704-2714 (2011).
44. Hulot, J.S. et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56, 134-143 (2010).
45. Liu, Y.P. et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb. Res. 128, 593-594 (2011).
46. Mega, J.L. et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304, 1821-1830 (2010).
47. Sofi, F., Marcucci, R., Gori, A.M., Giusti, B., Abbate, R. & Gensini, G.F. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated metaanalysis. Thromb. Haemost. 103, 841-848 (2010).
48. Jang, J.S. et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am. J. Cardiol. 110, 502-508 (2012).
49. Yang, L., Xie, J., Liu, Y. & Hu, X. Correlation between the genetic polymorphism of CYP2C192, 3 and the clinical efficacy of clopidogrel: a systematic review. Chin. J. Evid. Based Med. 12, 1063-1070 (2012).
50. Bhatt, D.L. et al.; CHARISMA Investigators. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur. Heart J. 33, 2143-2150 (2012).
51. Shuldiner, A.R., Vesely, M.R. & Fisch, A. CYP2C19 genotype and cardiovascular events. JAMA 307, 1482; author reply 1484-1485 (2012).
52. Sim, S.C. et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 79, 103-113 (2006).
53. Riley, R.D., Higgins, J.P. & Deeks, J.J. Interpretation of random effects metaanalyses. BMJ 342, d549 (2011).
54. Sterne, J.A.C. et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 343, (2011).
55. Poole, C. & Greenland, S. Random-effects meta-analyses are not always conservative. Am. J. Epidemiol. 150, 469-475 (1999).
56. Riley, R.D., Lambert, P.C. & Abo-Zaid, G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340, c221 (2010).
57. Smith, C.T., Williamson, P.R. & Marson, A.G. Investigating heterogeneity in an individual patient data meta-analysis of time to event outcomes. Stat. Med. 24, 1307-1319 (2005).
58. Altman, D.G. Systematic reviews of evaluations of prognostic variables. BMJ 323, 224-228 (2001).
59. Abo-Zaid, G., Sauerbrei, W. & Riley, R.D. Individual participant data metaanalysis of prognostic factor studies: state of the art? BMC Med. Res. Methodol. 12, 56 (2012).
60. Hemingway, H., Riley, R.D. & Altman, D.G. Ten steps towards improving prognosis research. BMJ 339, b4184 (2009).
61. Riley, R.D., Sauerbrei, W. & Altman, D.G. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br. J. Cancer 100, 1219-1229 (2009).
62. Ikediobi, O.N. et al.; UCSF Center for Translational and Policy Research on Personalized Medicine. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin. Pharmacol. Ther. 86, 28-31 (2009).
63. Deverka, P.A. Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12, 149-157 (2009).
64. Lesko, L.J., Zineh, I. & Huang, S.M. What is clinical utility and why should we care? Clin. Pharmacol. Ther. 88, 729-733 (2010).
65. McKinnon, R.A., Ward, M.B. & Sorich, M.J. A critical analysis of barriers to the clinical implementation of pharmacogenomics. Ther. Clin. Risk Manag. 3, 751-759 (2007).
66. Lu, C.Y., Karnon, J. & Sorich, M.J. The importance of high-quality evidence of the long-term impact of nonfatal events used in randomized controlled trials: a case study of prasugrel. Clin. Pharmacol. Ther. 90, 27-29 (2011).
67. Sorich, M.J., Vitry, A., Ward, M.B., Horowitz, J.D. & McKinnon, R.A. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data. J. Thromb. Haemost. 8, 1678-1684 (2010).